Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma

NICE technology appraisal guidance [TA226] Published date:

NICE recommends rituximab as a possible treatment to maintain remission in people with follicular non-Hodgkin's lymphoma.

You should be able to have rituximab maintenance treatment if your follicular non-Hodgkin's lymphoma has already responded to rituximab when given in combination with chemotherapy.

NICE looks at how well treatments work, and also at how well they work in relation to how much they cost the NHS. NICE recommended rituximab maintenance because it is clinically proven to prolong remission and its benefits to patients justifies its cost.

Get involved